Effects of the Probiotic Formulation VSL#3 on Colitis in Weanling Rats

Background: Only a few studies have used models of inflammatory bowel disease (IBD) with weanling animals. Previously, the effects of probiotics have not been assessed in such IBD models. The objectives of our study were 2-fold: to establish a suitable model of dextran sulfate sodium (DSS)–induced colitis in weanling rats and to determine the effects of the probiotic formulation VSL#3 on DSS-induced colitis in weanling animals. Materials and Methods: Rats were weaned on postnatal day 21 and administered 2%, 2.5%, or 3% (wt/vol) DSS in drinking water. In subsequent experiments, newly weaned animals were administered vehicle or VSL#3 (0.06, 0.6, or 6 mg) by orogastric gavage. These treatments were given to animals maintained on water (postnatal days 21–28) and then on DSS (postnatal days 28–35). Disease activity indices were determined on a routine basis. On day 35, rats were euthanized. The total colon length was determined. Other parameters of colitis were measured from the distal colon. These parameters included myeloperoxidase (MPO), interleukin (IL)–1β, inhibitory κB-α (IκB-α), and histological assessment of crypt damage and inflammation. Results: DSS 2% was optimal for inducing colitis in weanling rats without significant morbidity. VSL#3 treatments improved various parameters of 2% DSS–induced colitis in weanling rats. The 0.6- and 6-mg doses of VSL#3 were most effective for attenuating this colitis. Conclusions: The probiotic formulation VSL#3 improved DSS-induced colitis in weanling rats. This improvement of colitis involved changes in colonic IκB-α, IL-1β, and MPO, which are suggestive of immune modulation by VSL#3.

[1]  M. Neurath,et al.  Mouse models of inflammatory bowel disease. , 2007, Advanced drug delivery reviews.

[2]  W. Koltun,et al.  Dextran Sulfate Sodium-Induced Colitis Is Associated with Enhanced Low Molecular Mass Polypeptide 2 (LMP2) Expression and Is Attenuated in LMP2 Knockout Mice , 2006, Digestive Diseases and Sciences.

[3]  Ximing Xu,et al.  Melatonin Reduces Inflammatory Injury Through Inhibiting NF-κB Activation in Rats With Colitis , 2005, Mediators of inflammation.

[4]  M. Marinaro,et al.  Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse , 2005, Diabetologia.

[5]  Jide Wang,et al.  Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. , 2005, World journal of gastroenterology.

[6]  M. Marinaro,et al.  Probiotics Ameliorate Recurrent Th1-Mediated Murine Colitis by Inducing IL-10 and IL-10-Dependent TGF-β-Bearing Regulatory Cells1 , 2005, The Journal of Immunology.

[7]  F. Shanahan.  Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[8]  Michael Karin,et al.  Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.

[9]  Y. Tao,et al.  Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. , 2004, Gastroenterology.

[10]  K. Madsen,et al.  Probiotics and the management of inflammatory bowel disease. , 2004, Inflammatory bowel diseases.

[11]  C. De Simone,et al.  DNA from probiotic bacteria modulates murine and human epithelial and immune function. , 2004, Gastroenterology.

[12]  A. Andoh,et al.  Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. , 2004, International journal of molecular medicine.

[13]  S. Akira,et al.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. , 2004, Gastroenterology.

[14]  S. Ahrné,et al.  Modulation of the Effect of Dextran Sulfate Sodium-Induced Acute Colitis by the Administration of Different Probiotic Strains of Lactobacillus and Bifidobacterium , 2004, Digestive Diseases and Sciences.

[15]  H. Lehr,et al.  The Interleukin-1β-Converting Enzyme Inhibitor Pralnacasan Reduces Dextran Sulfate Sodium-Induced Murine Colitis and T Helper 1 T-Cell Activation , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  D. Seidner,et al.  The role of probiotics in gastrointestinal disease. , 2003, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[17]  Toshiaki Shimizu,et al.  The Relationship Between the Concentration of Dextran Sodium Sulfate and the Degree of Induced Experimental Colitis in Weanling Rats , 2003, Journal of pediatric gastroenterology and nutrition.

[18]  P. Brigidi,et al.  Variable Response to Probiotics in Two Models of Experimental Colitis in Rats , 2002, Inflammatory bowel diseases.

[19]  B. Siegmund.  Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation. , 2002, Biochemical pharmacology.

[20]  L. Fitzpatrick,et al.  Gliotoxin, an Inhibitor of Nuclear Factor-Kappa B, Attenuates Peptidoglycan-Polysaccharide-Induced Colitis in Rats , 2002, Inflammatory bowel diseases.

[21]  A. Ridderstad,et al.  Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides , 2002, International Journal of Colorectal Disease.

[22]  M. Grisham,et al.  Role of appendix and spleen in experimental colitis. , 2001, The Journal of surgical research.

[23]  C. De Simone,et al.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function. , 2001, Gastroenterology.

[24]  R. Sartor,et al.  Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. , 2001, Gastroenterology.

[25]  M. Büchler,et al.  Characterisation of Acute Murine Dextran Sodium Sulphate Colitis: Cytokine Profile and Dose Dependency , 2000, Digestion.

[26]  R. Sartor,et al.  NF‐κB signaling proteins as therapeutic targets for inflammatory bowel diseases , 2000 .

[27]  M. Farthing,et al.  Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis , 2000, Gut.

[28]  R. Sartor,et al.  The IκB/NF-κB system: a key determinant of mucosal inflammation and protection , 2000 .

[29]  A. Vetuschi,et al.  Dextran Sulfate Sodium (DSS) Colitis in Rats (Clinical, Structural, and Ultrastructural Aspects) , 1999, Digestive Diseases and Sciences.

[30]  S. Kitajima,et al.  Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. , 1999, Experimental animals.

[31]  A. Schottelius,et al.  A role for transcription factor NF-kB in intestinal inflammation , 1999, International Journal of Colorectal Disease.

[32]  H. Cooper,et al.  Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin , 1993, Digestive Diseases and Sciences.

[33]  T. Ohkusa,et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice , 1990 .

[34]  C. Jobin.  NF-KB Signaling Proteins as Therapeutic Targets for Inflammatory Bowel Diseases , 2007 .

[35]  À. Franch,et al.  Induction of Colitis in Young Rats by Dextran Sulfate Sodium , 2005, Digestive Diseases and Sciences.

[36]  R. Blumberg,et al.  The immunology of mucosal models of inflammation. , 2002, Annual review of immunology.

[37]  村野 実之.  Therapeutic effect of intracolonically administered nuclear factor κB (p65) antisense oligonucleotide on mouse dextran sulfate sodium (DDS)-induced colitis , 2000 .

[38]  L. Fitzpatrick,et al.  In vitro and in vivo effects of gliotoxin, a fungal metabolite: efficacy against dextran sodium sulfate-induced colitis in rats. , 2000, Digestive diseases and sciences.

[39]  S. Kitajima,et al.  Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. , 2000, Experimental animals.

[40]  D. Mack,et al.  Surface hydrophobicity of the intestinal tract. , 1992, The American journal of physiology.

[41]  Y. Benno,et al.  Development of Intestinal Microflora in Humans and Animals , 1986 .